RxDoctor Payments Data

Shewit Weldetensae, MD

Cardiovascular Disease · Modesto, CANPI 1972550150

Payments from drug & device makers

$343in general payments, 2019–2025

Across 21 payments — averaging $16.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$93
  • Johnson & Johnson$54
  • Amgen$46
  • Novartis$35
  • Medtronic$30
  • Boehringer Ingelheim$25
  • plus $61 from 4 others

What the payments were for

  • Food & beverage$32996%
  • Education$144%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$343 in reported general payments places this provider in the 20th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$461,903
Medicare patients
1,753
Services billed
5,278

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban196$177,020
JardianceEmpagliflozin81$63,608
XareltoRivaroxaban39$50,448
EntrestoSacubitril/Valsartan46$38,858
BrilintaTicagrelor37$37,721
Repatha SureclickEvolocumab38$37,232
FarxigaDapagliflozin Propanediol18$13,373
Ranolazine ErRanolazine61$6,583
Propafenone Hcl ErPropafenone Hcl14$3,773
Potassium Chloride165$3,572
Metoprolol Succinate296$3,106
Nifedipine ErNifedipine120$2,841
Losartan Potassium262$2,719
Atorvastatin Calcium241$2,285
Carvedilol188$1,707

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$12$177,020196 claims
Boehringer IngelheimJardiance$25$63,60881 claims
Johnson & JohnsonXarelto$54$50,44839 claims
NovartisEntresto$35$38,85846 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Modesto

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →